Loading company…
PairX Bio develops cancer immunotherapies based on tumor antigens produced by protein splicing.
PairX Bio is developing cancer immunotherapies targeting shared tumor-associated antigens produced by abnormal protein splicing. Its platform uses mRNA splicing biology and antigen and T cell validation procedures to identify tumor antigen-T cell pairs. Founded in 2020, the company is based in Singapore and was incubated by EVX Ventures after spinning out from Duke-NUS.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in